aprepitant · Heron Theraps Inc · NDA 209296
Cinvanti
Earliest generic entry, as listed
18 Sep 2035
Blocked by patent: US 10500208, US 10624850, US 10953018, US 11173118, US 11744800, US 12115254, US 12115255, US 12290520, US 9561229, US 9808465, US 9974742, US 9974793, US 9974794.
Listed patents · 13 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10500208 | product | 18 Sep 2035 |
| US 10624850 | use U-2161 | 18 Sep 2035 |
| US 10953018 | use U-2161 | 18 Sep 2035 |
| US 11173118 | product | 18 Sep 2035 |
| US 11744800 | product | 18 Sep 2035 |
| US 12115254 | product | 18 Sep 2035 |
| US 12115255 | product | 18 Sep 2035 |
| US 12290520 | product | 18 Sep 2035 |
| US 9561229 | product, use U-2161 | 18 Sep 2035 |
| US 9808465 | use U-2161 | 18 Sep 2035 |
| US 9974742 | product | 18 Sep 2035 |
| US 9974793 | product | 18 Sep 2035 |
| US 9974794 | product, use U-2161 | 18 Sep 2035 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 209296 · 001 · RLD | emulsion, intravenous | 130MG/18ML (7.2MG/ML) | 18 Sep 2035 |